LIST OF TABLES

CHAPTER 1: INTRODUCTION

Table 1.1: Anti-viral drug therapy approved for ocular viral infections 1

CHAPTER 2: LITERATURE OVERVIEW

Table 2.1: List of different nano-carriers explored by different investigator as possible topical ocular drug delivery carrier 35
Table 2.2: List of mucoadhesive nano-systems investigated in recent years for enhanced ocular retention and bioavailability of drugs 43

CHAPTER 3: BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF GANCICLOVIR

Table 3.1: Method validation data for quantification of GCV in aqueous humor by UHPLC 51

CHAPTER 4: BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF CYCLOSPORINE A

Table 4.1: Method validation data for Cyclosporine A in aqueous humor, plasma, Conjunctiva, Cornea 61

CHAPTER 5: GANCICLOVIR NIOSOMAL NANOFORMULATION

Table 5.1: Independent and dependent variables for Niosome using span 60 70
Table 5.2: Independent and dependent variables for Niosome using span 40 71
Table 5.3: Different runs with varying levels of independent variables as generated by Design Expert® 8.0 software and obtained dependent variable (size and entrapment efficiency) of span60 based niosomal formulations 83
Table 5.4: Different runs with varying levels of independent variables as generated by Design Expert® 8.0 software and obtained dependent variable (size and entrapment efficiency) of span40 based niosomal formulations 83
Table 5.5: Fit Summary of different mathematical models for span60 niosome size 85
Table 5.6: Fit Summary of different mathematical models for span40 niosome size 85
Table 5.7: Analysis of variance table for S60 size 86
Table 5.8: Analysis of variance table for S40 size 87
Table 5.9: Fit Summary of different mathematical models for S60 entrapment efficiency 99
Table 5.10: Fit Summary of different mathematical models for S40 entrapment efficiency 99
Table 5.11: Analysis of variance table for S60 %EE 100
Table 5.12: Analysis of variance table for S40 %EE 101
Table 5.13: Final equation in terms of coded factors 112
Table 5.14: Selected formulations and their characterization parameters 113
Table 5.15: Steady state flux (Jss), Permeation coefficient (Kp) and enhancement ratio (ER) of GCV from niosomes and control (GCV solution) (mean ± SD, n = 3) 118
Table 5.16: % Activity remaining, AUC0→30 min for GCV-MNDs compared with GCV-sol after topical application onto the rabbit eye 121
Table 5.17: % Activity remaining, AUC0→30 min for GCV-NDs compared with GCV-sol after topical application onto the rabbit eye 123
Table 5.18: Pharmacokinetic parameters of GCV after topical instillation of GCV solution and GCV niosomal formulations to rabbit eye 126

CHAPTER 6: CYCLOSPORINE A NANOEMULSION FORMULATION

Table 6.1: Solubility of cyclosporin A in different oils 142
Table 6.2: Solubility of cyclosporin A in surfactants and co-surfactants 144
Table 6.3: Oil, surfactants cosurfactant and their combination ratios used for the optimization of surfactant 145
Table 6.4: Nanoemulsion points for the mixture containing Smix ratio 1:1 Oil phase- oleic acid, Smix- surfactant: cosurfactant, Surfactant: tween20, Cosurfactant: Transcutol P 145
Table 6.5: Nanoemulsion points for the mixture containing Surfactant/ Co-Surfactant ratio 1:1, Oil phase: Oleic acid, Surfactant: Cremophore EL, Cosurfactant: Transcutol P 148
Table 6.6: Nanoemulsion points for the mixture containing S/ CoS ratio 1:1, Oil phase: Oleic acid, Surfactant: Tween 80, Cosurfactant: Transcutol P 151
Table 6.7: Nanoemulsion points for the mixture containing S/CoS ratio 1:1, Oil phase: Oleic acid, Surfactant: Labrasol, Cosurfactant: Transcutol P.

Table 6.8: The titrating combination of oil, smix ratio and number of new points obtained

Table 6.9: Nanoemulsion points for the mixture containing S/CoS ratio 1:0, Oil Phase: Oleic acid., Surfactant: Tween 20, Cosurfactant: Nil

Table 6.10: Nanoemulsion points for the mixture containing S/CoS ratio 2:1, Oil phase: Oleic acid, Surfactant: Tween 20, Cosurfactant: Transcutol P.

Table 6.11: Nanoemulsion points for the mixture containing S/CoS ratio 1:2 Oil phase: Oleic acid, Surfactant: Tween 20, Cosurfactant: Transcutol P.

Table 6.12: Nanoemulsion points for the mixture containing S/CoS ratio 3:1 Oil phase: Oleic acid, Surfactant: Tween 20, Cosurfactant: Transcutol P.

Table 6.13: Nanoemulsion points for the mixture containing S/CoS ratio 1:3. Oil Phase: Oleic acid, Surfactant: Tween 20, Cosurfactant: Transcutol P.

Table 6.14: Nanoemulsion points for the mixture containing S/CoS ratio 4:1 Oil phase: Oleic acid, Surfactant: Tween 20, Cosurfactant: Transcutol P.

Table 6.15: Nanoemulsion points for the mixture containing S/CoS ratio 1:0 Oil Phase: Oleic acid, Surfactant: Cremophore EL, Cosurfactant: Nil

Table 6.16: Nanoemulsion points for the mixture containing S/CoS ratio 1:2 Oil phase: Oleic acid, Surfactant: Cremophore EL, Cosurfactant: Transcutol P.

Table 6.17: Nanoemulsion points for the mixture containing S/CoS ratio 2:1 Oil Phase: Oleic acid, Surfactant: Cremophore EL, Cosurfactant: Transcutol P.

Table 6.18: Nanoemulsion points for the mixture containing S/CoS ratio 1:3, Oil Phase: Oleic acid, Surfactant: Cremophore EL, Cosurfactant: Transcutol P.

Table 6.19: Nanoemulsion points for the mixture containing S/CoS ratio 3:1 Oil phase: Oleic acid, Surfactant: Cremophore EL, Cosurfactant: Transcutol P.

Table 6.20: Thermodynamic stability testing result of different selected nanoemulsion formulations
Table 6.21: Selected Nanoemulsions, mucoadhesive nanoemulsion formulation and their characterization parameters

Table 6.22: % Activity remaining, AUC0→30 min for CYA mucoadhesive NEs formulation (CH-B1) as compared to non mucoadhesive formulation (B1) after topical application onto the rabbit eye

CHAPTER 7: SAFETY STUDY OF GANCICLOVIR MUCAOADHESIVE NIOSOME AND CYCLOSPORINE A MUCAOADHESIVE NANOEMULSION

Table 7.1: Table 7.1: Scoring scheme for hyperaemia, haemorrhage and coagulation in HET-CAM test for ocular irritation study

Table 7.2: Cumulative scores for assessment of ocular irritation potential

Table 7.3: The obtained irritating scores for MNDs, MNEs, negative and positive control (HET-CAM) test

Table 7.4: Ocular surface temperature (°C±S.D; for three measurement) measurement by IR Camera for MNDs and MNEs